BPS Oncology Pharmacy Certification Examination Practice Test
Oncology pharmacy practice applies cancer pharmacotherapy to treatment planning, supportive care, and medication safety. BCOP practice questions use clinical situations involving antineoplastic toxicities, infusion reactions, interactions, immunosuppression, and complications such as malignancy-associated hypercalcemia. The focus is on recognizing treatment-related risks and connecting patient findings with appropriate pharmacy assessment and intervention.
Exam overview
About the BPS Oncology Pharmacy Certification Examination Exam
Oncology pharmacists evaluate therapy in the context of the cancer regimen, treatment schedule, route, and patient-specific risks. This includes identifying urgent adverse effects, distinguishing acute infusion reactions from delayed toxicities, and recognizing when symptoms such as chest pain, diarrhea, or neurologic changes require prompt evaluation. Safe medication management also involves reviewing interactions that can alter anticancer or supportive-care drug exposure, assessing infection and reactivation risks during immunosuppressive therapy, and selecting appropriate monitoring for agents with characteristic toxicities. Supportive-care decisions may involve symptom control, antiemetic regimens, vaccination considerations, and management of metabolic complications. Effective practice requires interpreting medication histories and clinical findings, prioritizing safety concerns, and communicating actionable recommendations to the oncology care team.
Sample Practice Questions
Review a selection from this exam's published US Practice Tests practice bank.
A patient is scheduled to receive a monoclonal antibody infusion and develops chills, flushing, and shortness of breath during the infusion. What is the immediate priority?
Show answer
Correct answer: ASymptoms during an infusion may indicate an infusion-related reaction. The infusion should be stopped or paused, and the patient assessed and managed according to severity and the institution’s protocol. Restarting, if appropriate, depends on clinical evaluation and protocol guidance.
A patient receiving continuous-infusion fluorouracil develops chest pressure and electrocardiographic changes during treatment. Which potential adverse effect should be considered urgently?
Show answer
Correct answer: AFluoropyrimidines such as fluorouracil can cause cardiotoxicity, including coronary vasospasm, ischemia, and other cardiac events. New chest symptoms during treatment require urgent clinical assessment and communication with the oncology team.
A patient receiving irinotecan develops acute abdominal cramping, sweating, and diarrhea during the infusion. Which medication is commonly used to manage this acute cholinergic syndrome?
Show answer
Correct answer: AIrinotecan can cause an acute cholinergic syndrome during or shortly after infusion. Atropine is commonly used to treat or prevent these acute symptoms. Delayed irinotecan diarrhea is managed differently, often with loperamide and clinical assessment.
A patient receiving an anti-CD20 monoclonal antibody is hepatitis B surface antigen negative but has a positive hepatitis B core antibody. Why is this finding clinically important before treatment?
Show answer
Correct answer: BA positive hepatitis B core antibody can reflect prior infection, even when surface antigen is negative. B-cell-depleting therapy can reactivate hepatitis B, so patients need appropriate evaluation and a prevention or monitoring plan based on clinical risk and current guidance.
A patient with cancer is receiving high-dose cytarabine. Which monitoring concern is particularly important because of a characteristic dose-related toxicity?
Show answer
Correct answer: AHigh-dose cytarabine can cause cerebellar toxicity, including ataxia, dysarthria, and nystagmus. Neurologic assessment during treatment is important, and new findings should be reported promptly for clinical evaluation and treatment decisions.
A patient with cancer is receiving oral prednisone at a prolonged immunosuppressive dose. Which vaccination approach is generally preferred when an indicated vaccine is needed during substantial immunosuppression?
Show answer
Correct answer: CLive attenuated vaccines may pose a risk during significant immunosuppression. Non-live vaccines are generally preferred when vaccination is appropriate, although immune response may be reduced. Timing should be individualized with the oncology and prescribing teams.
A patient receiving vincristine reports new numbness in the fingers and difficulty fastening buttons. Which toxicity is most consistent with these symptoms?
Show answer
Correct answer: AVincristine can cause dose-limiting peripheral neurotoxicity, including sensory symptoms and impaired fine motor function. Assessing symptom severity and function helps guide clinical evaluation and possible treatment modification.
How to use this practice test
The free US Practice Tests bank contains 50 BCOP practice questions. Each session presents up to 20 randomly selected questions, with results shown after the session. Use the scenarios to practice identifying toxicity patterns, interaction risks, and immediate assessment priorities; review missed items by tracing the patient finding back to the likely medication-related concern.
Preparation tips
- For each antineoplastic agent in a case, connect the reported symptom and timing to its characteristic toxicity; distinguish infusion-time reactions from cumulative or delayed effects.
- Practice triaging urgent findings such as chest pressure during fluorouracil, acute symptoms during an infusion, or new sensory changes during vincristine therapy.
- Review interaction pathways that affect oncology care, including CYP2D6 inhibition with tamoxifen and aprepitant-related effects on hormonal contraceptive reliability.
- Compare infection-prevention decisions for immunosuppressed patients, including hepatitis B reactivation risk with anti-CD20 therapy and vaccine selection during substantial immunosuppression.
- Pair supportive-care interventions with the problem being treated, such as antiemetic use, acute irinotecan cholinergic symptoms, and bone-resorption treatment for malignancy-associated hypercalcemia.